CINXE.COM

<?xml version="1.0" encoding="utf-8"?> <rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>PharmaVoice - Latest News</title><link>https://www.pharmavoice.com/news/</link><description>News for pharmacy pros</description><atom:link href="https://www.pharmavoice.com/feeds/news/" rel="self"></atom:link><language>en-us</language><lastBuildDate>Thu, 20 Feb 2025 08:00:00 -0500</lastBuildDate><item><title>Lilly’s former M&A chief scours the landscape for potential deals as Immunocore’s new CFO</title><link>https://www.pharmavoice.com/news/immunocore-cfo-business-pharma-eli-lilly-kimmtrak-travis-coy/740447/</link><description><p>Travis Coy is using his Big Pharma bona fides to prioritize business development at the diversified and growing company.</p></description><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Michael Gibney</dc:creator><pubDate>Thu, 20 Feb 2025 08:00:00 -0500</pubDate><guid>https://www.pharmavoice.com/news/immunocore-cfo-business-pharma-eli-lilly-kimmtrak-travis-coy/740447/</guid></item><item><title>Challenges mount for vaccine makers</title><link>https://www.pharmavoice.com/news/vaccine-makers-earnings-report-flu-rsv-moderna-pfizer-sanofi/740290/</link><description><figure><div><img src="https://imgproxy.divecdn.com/Xqz8eVR3KG3O6t74jNYlm9cnyLo8TK4p0NPv3xHkXn4/g:nowe:0:553/c:4958:2801/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMDg0MDA2MjYwLmpwZw==.webp"/></div></figure><p>End-of-year earnings reports reveal drugmakers are grappling with declining vaccination rates and an unpredictable Trump administration.</p></description><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Amy Baxter</dc:creator><pubDate>Wed, 19 Feb 2025 07:43:33 -0500</pubDate><guid>https://www.pharmavoice.com/news/vaccine-makers-earnings-report-flu-rsv-moderna-pfizer-sanofi/740290/</guid></item><item><title>Merck, Lilly launch manufacturing R&D consortium to help ‘bolster’ U.S. production</title><link>https://www.pharmavoice.com/news/merck-lilly-manufacturing-purdue-pharma-drug/740248/</link><description><figure><div><img src="https://imgproxy.divecdn.com/nKGpxStAeW31SdPTJ9-Z-aXgILiSDxUVe3hwjjbPNvg/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNDE3Mzk1NzI3LmpwZw==.webp"/></div></figure><p>The Young Institute Pharmaceutical Manufacturing Consortium will research and develop new production technologies.</p></description><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Alexandra Pecci</dc:creator><pubDate>Wed, 19 Feb 2025 07:43:24 -0500</pubDate><guid>https://www.pharmavoice.com/news/merck-lilly-manufacturing-purdue-pharma-drug/740248/</guid></item><item><title>CRISPR’s cardio catch-all drives a biotech’s broad potential</title><link>https://www.pharmavoice.com/news/crispr-cardio-biotech-scribe-therapeutic/740169/</link><description><figure><div><img src="https://imgproxy.divecdn.com/NWZXFr1PnKPXDu6yg9Sc_SX_Fb5eBIbNrb3l2q-D8ng/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xODIwNTMzMzM0LmpwZw==.webp"/></div></figure><p>Scribe Therapeutics hopes to prevent cardiometabolic diseases by targeting underlying causes with CRISPR technology.</p></description><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kelly Bilodeau</dc:creator><pubDate>Tue, 18 Feb 2025 08:00:00 -0500</pubDate><guid>https://www.pharmavoice.com/news/crispr-cardio-biotech-scribe-therapeutic/740169/</guid></item><item><title>Salesforce or Veeva: How drugmakers can navigate the upcoming CRM split</title><link>https://www.pharmavoice.com/news/veeva-salesforce-split-pharma-biotech-navigate-divorce/739985/</link><description><figure><div><img src="https://imgproxy.divecdn.com/HZ3Gx3Xsd15cQjJ_enTdhOKclyKeZTCd9VX1r5oWYEk/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy00NzUyNDA5NTIuanBn.webp"/></div></figure><p>The two companies will let their long-running contract expire this year, and drugmakers will need to decide which is the best platform for them in a changing marketplace.</p></description><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Michael Gibney</dc:creator><pubDate>Thu, 13 Feb 2025 07:54:11 -0500</pubDate><guid>https://www.pharmavoice.com/news/veeva-salesforce-split-pharma-biotech-navigate-divorce/739985/</guid></item><item><title>The kids are alright: How pharma can make inroads with Gen Z</title><link>https://www.pharmavoice.com/news/pharma-inroads-with-gen-z-marketing/739856/</link><description><figure><div><img src="https://imgproxy.divecdn.com/EIhsKP8vxW8ehM_dXvDr-nA05sw7ynF7p1JY2FGNX5c/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTUyNjM3ODQwLmpwZw==.webp"/></div></figure><p>As drug development priorities shift, pharma companies need to understand younger patients to improve their reputation.</p></description><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Amy Baxter</dc:creator><pubDate>Wed, 12 Feb 2025 08:00:00 -0500</pubDate><guid>https://www.pharmavoice.com/news/pharma-inroads-with-gen-z-marketing/739856/</guid></item><item><title>In the crowded cardio space, it’s David vs. Goliath for small biotechs</title><link>https://www.pharmavoice.com/news/cardio-tourmaline-bio-drug-novo/739738/</link><description><figure><div><img src="https://imgproxy.divecdn.com/-_-j1ksVvt--CzTabcyO04fqPKqSm8e8ryaYmMbBK0g/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMzg3Mjk4OTE3LmpwZw==.webp"/></div></figure><p>What will it take for a clinical-stage biotech to break into the cardio space? One CEO thinks he has the answer.</p></description><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Alexandra Pecci</dc:creator><pubDate>Tue, 11 Feb 2025 07:27:12 -0500</pubDate><guid>https://www.pharmavoice.com/news/cardio-tourmaline-bio-drug-novo/739738/</guid></item><item><title>Medicare’s next list of drugs for price negotiation could get ‘very interesting’ — and have a bigger impact on pharma</title><link>https://www.pharmavoice.com/news/medicare-drug-pricing-negotiation-ira-trump-pharma-impact/739742/</link><description><figure><div><img src="https://imgproxy.divecdn.com/93MvjaW74fl4paBYJGiOXU72078-VujGJ42YT64QreA/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTYzMzA1NDIwLmpwZw==.webp"/></div></figure><p>The Biden-era law is now in the hands of a new administration, and drugmakers are scanning the horizon for hints of a massive overhaul or incremental change.</p></description><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Michael Gibney</dc:creator><pubDate>Tue, 11 Feb 2025 07:25:59 -0500</pubDate><guid>https://www.pharmavoice.com/news/medicare-drug-pricing-negotiation-ira-trump-pharma-impact/739742/</guid></item><item><title>Are orexins the next golden child of neuroscience?</title><link>https://www.pharmavoice.com/news/orexin-neuroscience-alkermes-takeda-narcolepsy/739607/</link><description><figure><div><img src="https://imgproxy.divecdn.com/n6RYQi6pb-PnXl30Np0XovxIJA5VEolKP0cjt-vcPkI/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNDQ5MzM3MzcxXzEuanBn.webp"/></div></figure><p>An emerging class of orexin-based drugs are on the cusp of disrupting care for sleep disorders &mdash; and potentially much more.</p></description><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Meagan Parrish</dc:creator><pubDate>Mon, 10 Feb 2025 08:00:00 -0500</pubDate><guid>https://www.pharmavoice.com/news/orexin-neuroscience-alkermes-takeda-narcolepsy/739607/</guid></item><item><title>Beyond GLP-1s? This biotech is exploring longer-term metabolic treatments</title><link>https://www.pharmavoice.com/news/biotech-long-term-metabolic-glp1-fractyl-health/739606/</link><description><p>Fractyl Health is entering pivotal studies for a procedure that aims to be an &lsquo;off ramp&rsquo; to GLP-1s and exploring how a one-time, &lsquo;smart GLP-1&rsquo; gene therapy can Treat type 2 diabetes.</p></description><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Amy Baxter</dc:creator><pubDate>Mon, 10 Feb 2025 08:00:00 -0500</pubDate><guid>https://www.pharmavoice.com/news/biotech-long-term-metabolic-glp1-fractyl-health/739606/</guid></item></channel></rss>